Case Study – Hospitales Universitarios Virgen de las Nieves and Clínico San Cecilio

Challenge

Rare & Inherited Diseases

Solution

SOPHiA DDM™

Country

Spain

The Andalusian Health Service conduct trio analysis with the SOPHiA DDM™ Platform to identify the underlying cause of 2 neonatal deaths

The Genetics Laboratories at the Hospitales Universitarios Virgen de las Nieves and Clínico San Cecilio in Granada, Spain are affiliated with the Andalusian Health Service (Servicio Andaluz de Salud) and act as reference laboratories for the Andalusian region, primarily investigating inherited diseases and assessing hereditary cancers. The laboratories receive and analyze hereditary cancer samples from a 1.5 million-person reference population across Granada and Huelva, assessing approximately 1000 samples per year.

Research Case

A couple, who were discovered to be consanguineous, birthed a healthy daughter in 2012 and then had two further children both of whom died before they were 2 months old – a 43 day-old male in 2019 and a 20 day-old female in 2022. In 2019, a sample from the male neonate was sent to an external laboratory for exome and targeted sequencing, with inconclusive results. Microarray-based comparative genomic hybridization (aCGH) was also conducted, but no anomalies were detected. In 2022, the H. Virgen de las Nieves and Clínico San Cecilio laboratories received a sample from the 20-day-old female neonate to investigate the underlying cause(s) that may have led to her death.

Approach

The H. Virgen de las Nieves and Clínico San Cecilio laboratories used the SOPHiA DDM™ Platform to conduct familial variant analysis (FVA) on a trio of samples from the mother, father, and female neonate proband, using clinical exome data. This allowed them to look for inheritance patterns to determine whether pathogenic variant(s) were inherited or if the mutation was de novo.

Results

The SOPHiA DDM™ Platform identified a homozygous variant of unknown significance in the proband, that caused a frameshift in the SMPD4 gene: NM_001171083.2 (SMPD4) c.444_445del p.(Ala149Leufs*52). The FVA found that the variant was heterozygous in both parents and homozygous in the proband, and after further investigation also homozygous in the male neonate, suggesting an autosomal recessive inheritance. The mutation was confirmed by orthogonal testing. SMPD4 has previously been associated with neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies (NEDMABA), aligning clinically with the neonates’ phenotypes.

Watch our SOPHiA GENETICS Product Manager Paul Dougall present this case study at ACMG 2022

Watch Webinar

Related Case Studies

Case Study: Unlocking access to MSK-ACCESS® for robust liquid biopsy analysis Read More

Genomic Diagnostics, Australia Read More

TomaLab Advanced Biomedical Assays Read More

1 2 3 … 5 Next »

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services